Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma
{{output}}
Background: Enfortumab vedotin (EV) + pembrolizumab (P) is now first-line standard-of-care for locally advanced or metastatic urothelial carcinoma (la/mUC) after the phase 3 EV-302 trial doubled overall survival (OS) vs. platinum... ...
